Peripheral arterial disease (PAD) affects a large percentage of the elderly population. Standard invasive treatment, apart from risk factor modulation, consists of bypass surgery or percutaneous transluminal angioplasty. However, symptomatic recurrence rates are high for both procedures and a substantial part of the patient population with PAD is not a candidate for invasive revascularization due to complexity of the lesion and/or co-morbidity. Therapeutic arteriogenesis has been proposed as an alternative treatment option. The present paper describes the design of the START-trial. This trial aims to determine the potential of the proarteriogenic substance granulocyte/macrophage colony stimulating factor (GM-CSF) to increase maximal walking distance in patients with intermittent claudication. A double-blinded, randomized, placebo-controlled study will be performed in 40 patients with peripheral obstructive arterial disease Rutherford grade I, category 2 or 3, that are candidates for bypass surgery or percutaneous transluminal angioplasty. Based on pharmacokinetic and toxicologic studies, a dose of 10 mg/kg will be used. Patients will be treated for a period of 14 days on each consecutive day, with the last injection applied on day 12. The primary endpoint will be the change in walking distance from day 0 to day 14 as assessed by an exercise treadmill test. Secondary endpoints will be the ankle-brachial index at rest and after exercise, the pain-free walking distance and cutaneous microcirculatory alterations as assessed by laser Doppler uxmetry. Iliac ow reserve and conductance will be measured by magnetic resonance imaging.
Introduction
The age-adjusted prevalence of peripheral arterial disease (PAD) is about 12%, of whom approximately one-third suffers from typical intermittent claudication. 1 A relatively benign natural history in combination with secondary prevention and exercise, results in a large fraction of patients with no changes or even improvement of symptoms. 2 However, a minority of patients go on to need de nitive treatments in the form of percutaneous transluminal angioplasty (PTA) or surgical revascularization. The mortality and morbidity of PTA and bypass surgery are nowadays relatively low, although peri-operative infection of arterial reconstructions is still associated with high rates of mortality and limb loss. 3 Moreover, a signi cant number of patients with femoro-popliteal disease will be rehospitalized due to restenosis of the treated lesion or progression of other lesions. In a recently published study, a total of 46% of all patients required one or more re-interventions within 12 months after femoro-distal bypass surgery. 4 Similarly, high restenosis rates have been reported after PTA, 5 with actually very poor results for long lesions. 6 Finally, the costs of these procedures is high, warranting the evaluation of alternative treatment strategies.
Pre-existing collateral vessels develop in non-ischaemic tissue upon arterial narrowing or occlusion and connect these regions with under-perfused vascular territories, a process referred to as arteriogenesis. 7 ,8 In approximately 25% of patients with PAD, the peripheral circulation displays a natural ability to adapt very well to arterial obstruction leading to an actual diminishing of physical complaints, and it is assumed that the improvement of symptoms in this group of patients is based on an increase of the capacity of the collateral circulation via arteriogenesis. 2 However, in a large group of patients, arteriogenesis is not suf cient to restore blood ow and meet the oxygen demand of regions distal of the arterial occlusion. A pharmacological therapy, stimulating collateral artery formation, would be a valuable adjuvant or alternative therapy for PTA or bypass surgery in this group of patients.
Several growth factors display arteriogenic properties in experimental animal studies. 9 -1 2 In the present study, we have selected granulocyte/macrophage colony stimulating factor (GM-CSF) as a potential pro-arteriogenic factor. This factor has also been shown to have a pro-arteriogenic effect in an experimental setting. 1 3 GM-CSF is already available as a pharmaceutical compound. It is used, for example, to treat leukopenia as observed after chemotherapy. This implies that extensive documentation is available on toxicity, side effects and dosage regimens -at least in this group of patients. Another advantage of GM-CSF is the subcutaneous administration, avoiding cumbersome invasive procedures to deliver the substance. Finally, preliminary ndings suggest that GM-CSF is effective in stimulating the development of the collateral circulation in patients with coronary artery disease (CAD). 1 4 The START-trial (STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease) is designed to test the effects of GM-CSF in patients with PAD and is set up as a 'proof-of-principle' study. Therefore, the primary outcome of the START-trial is the change in treadmill walking distance from day 0 to day 14, analogous to the previously mentioned study by Seiler and colleagues in patients with CAD. 1 4 Moreover, in our experimental studies, effects were seen directly following a 7-day treatment. 1 3 In this set-up, conventional revascularization therapy, if deemed necessary, is not withheld from patients beyond the 14-day treatment period. In addition to treadmill walking distance, the ankle-brachial index (ABI) will be used for evaluation of peripheral dynamics.
Finally, the feasibility of magnetic resonance imaging (MRI)-derived measurements of iliac ow reserve and conductance as potential new parameters to detect changes in the capacity of the peripheral collateral circulation will be determined. For all patients, measurements will be repeated at day 90, irrespective of the performance of an invasive procedure between day 14 and day 90.
Methods

Study population
A total of 40 patients will be selected to enter the study, randomly distributed over a treatment and a control group. Patients will have intermittent claudication and would be candidates for PTA or bypass surgery. Patients will be considered eligible for the study if an obstructive lesion or severe stenosis (peak systolic velocity ratio >2.5 on duplex or diameter reduction >50% on angiography) is present in the peripheral circulation, the criteria for Rutherford grade I, category 2 or 3, are ful lled and walking distance at a standard treadmill test examination is repeatedly below 266 meters. Furthermore, walking distance needs to be limited due to speci c symptoms of intermittent claudication and not due to shortness of breath, angina, arthritis or other complaints not directly related to PAD. Inclusion and exclusion criteria are shown in Table 1 . Medication of patients will not be changed during the study protocol. Patients will be recruited at the Academic Medical Center (AMC) Amsterdam and the Rijnland Hospital Leiderdorp in The Netherlands, as well as from the University Clinic Freiburg, Germany. 
Inclusion criteria
· Symptomatic patients with PAOD, Rutherford grade I, category 2 or 3 · Obstructive lesion or severe stenosis (PSV ratio >2.5 on duplex or diameter reduction >50% on angiography) · Candidates for bypass operation or PTA
Exclusion criteria
· Clinical or laboratory signs of chronic or acute in ammation · Previous or current history of neoplasm · Diabetes · Pregnancy or preserved child-bearing capabilities · Refusal or inability to give informed consent PAOD, peripheral arterial occlusive disease; PSV, peak systolic velocity; PTA, percutaneous transluminal angioplasty
Study design and intervention
The study will be conducted in accordance with the principles of the Declaration of Helsinki and is designed as a double-blinded, randomized and placebo-controlled trial comparing GM-CSF treatment with placebo in a 1:1 ratio. Patients will be treated with recombinant GM-CSF (rGM-CSF) at a dosage of 10 mg/kg per injection (either Leukine, Berlex or Leucomax, Scheringh-Plough) or with placebo. The use of different suppliers of rGM-CSF is an unplanned deviation from the protocol, caused by a sudden termination of distribution by Schering-Plough from December 1, 2002. Placebo consists of 0.1% albumin in aqua ad injectionem. Injections are subcutaneous and applied at days 0, 2, 4, 6, 8, 10 and 12. In the weeks following termination of treatment, patients will be seen by a physician and a decision made regarding whether or not to perform PTA or bypass surgery. Both physician and patient will still be blinded to the medication at the time of this decision.
Hypothesis
In the current study, we will test the hypothesis that repetitive subcutaneous application of GM-CSF increases maximal walking distance in patients with intermittent claudication, 14 days after initiation of treatment.
Measurements
Measurements will be performed by independent investigators at baseline and day 14. The primary endpoint consists of the maximum walking distance at day 14. Therefore, a treadmill walking test will be performed with the speed set at 3.2 km/h and the slope at 8%. Additional secondary endpoints consist of pain-free walking distance and ABI at rest and after exercise. With the use of a pneumatic cuff and a continuous-wave Doppler system, ABI is derived from the highest measured leg pressure divided by the highest measured arm pressure. ABI measurements are performed both at rest and directly following exercise. All measurements will be repeated at day 90. Figure 1 shows a owchart for the entire study.
In all patients that are included from either the AMC or the Rijnland Hospital, skin microcirculatory perfusion will be assessed by means of laser Doppler (Peri ux 4001 Ò , Perimed, Sweden) as previously described. 1 to the pulp of the hallux using its probe holder and doublesided adhesive tape. Laser Doppler Fluxometry (LDF) is measured on the pulp of the toes, since this area has a large number of arteriovenous anastomoses as opposed to the dorsum of the foot. Measurements are performed at rest with the patient in the supine position and the foot at heart level. In addition, LDF is recorded during reactive hyperaemia, after a 3-minute arterial occlusion induced by in ating a cuff above the ankle. The biological zero ux (the basal LDF during arterial occlusion) is subtracted from all LDF values measured. In another subset of 15 patients, volume ow measurements will be performed using non-contrast MRI with 2D phase contrast technique. Total in ow is measured at the level of the common iliac artery, both at rest and during reactive hyperaemia. Therefore, for this sub-study, only patients with patent common iliac arteries are eligible. To induce hyperaemia, a pneumatic cuff is applied around the thigh and in ated to 200 mmHg for 1 minute. Flow measurements are then performed directly following release of the cuff. Iliac ow reserve is calculated as hyperaemic ow divided by baseline ow. Volume ow measurements and ABI are combined to calculate conductance. Conductance is the reciprocal value of resistance and re ects the maximal ow capacity of a circulatory system. Formulae for iliac ow reserve and conductance are shown in Figure  2 . The feasibility of the iliac ow reserve measurement was tested in a small group of healthy volunteers as well as in patients suffering from unilateral PAD. The results from a Figure 4 shows the measurements of conductance of the non-affected normal leg versus the affected leg in a patient suffering from PAD.
Blood samples will be collected at days 0, 2, 4, 6, 8, 10, 12 and 14 and at 3 months follow-up for measurements of total leukocytes, differentiated blood count, creatinine, C-reactive protein, SGOT, SGPT, albumin, triglycerides, total cholesterol, VLDL, LDL, HDL and homocystein. Monocytes will be isolated via a Ficoll gradient according to standard procedures and changes in expression pro les will be determined with the use of mRNA pro ling techniques (gene arrays and subsequent RT-PCR). Flow cytometry analysis will be performed on whole blood, using CD14 as a marker of human monocytes, and MAC-1 as a marker of monocyte activation.
Finally, repeat eye examinations will be performed to exclude induction of retinopathy by rGM-CSF treatment. Therefore, a digital photograph of the retina will be performed under conditions of pupil dilation. Of each eye, two photographs are made under opposite angles of 55 degrees and then scored for absence or presence of retinopathy. In case of the presence of retinopathy, any worsening, stability or improvement of disease are documented.
Sample size
Sample size is set at 40 patients. Placebo effect in this group of patients is approximately 40%. In the recently published TRAFFIC trial, a 2.5-fold increase in walking distance was found in patients treated with b-FGF compared with the placebo group. 1 6 We therefore aim at a comparable effect of treatment in the present study. Mean walking distance in patients with Rutherford grade I, category 2 or 3, is 87 meters with a standard deviation of 54 meters (own data, based on observations in 3500 patients that visited the vascular laboratory at the AMC). A 2.5-fold increase in mean walking distance would result in 217.5 
Randomization
Patients will be randomized into groups with the use of a computer-generated randomization list in a 1:1 ratio. Randomization wil be primarily performed by BA and reported to JO for patients included in the Rijnland Hospital and to SHS for patients included in the University Clinic Freiburg. BA, JO and SHS are responsible for administration of the study drug but are not involved in data analysis or manuscript preparation. All other study personnel and participants will be blinded to treatment assignment for the duration of the study.
Statistics
For primary analysis, an independent samples t-test will be used to test whether the change in log-transformed maximal walking distance (between baseline and day 14) is different between the two treatment groups. The primary analysis excludes patients that are not available for follow-up. A one-sample t-test will be applied to test whether the change in log-transformed walking distance is statistically signicant within each treatment group. Statistical signi cance is assumed at p < 0.05. Analyses involving the secondary endpoints will be carried out as subsidiary analyses. For comparison of endpoints at day 90 between the GM-CSFtreated group and the placebo group, patients that have received a revascularization procedure before day 90 will be excluded.
Discussion
Our own experimental data on the arteriogenic potential of GM-CSF, supported by the clinical data derived from the study by Seiler et al in patients with CAD, 1 4 prompted us to design the START-trial. All patients are candidates for PTA or bypass surgery. It is not our intention to withhold patients' standard interventional therapy and therefore the decision to perform such therapy following the 14-day treatment period and assessment of our primary endpoint is left to the discretion of the patient and the treating physician. Patients as well as physicians are blinded to treatment during the complete follow-up period of 90 days. The present study is merely designed as a 'proof-of-principle' study on whether the course of PAD can be modi ed pharmacologically via stimulation of collateral artery growth using subcutaneously applied GM-CSF.
Non-invasive treatment of PAD is mainly limited to walking exercise and risk factor modulation via smoking cessation, treatment of hyperlipidaemia, anti-hypertensive drugs, anti-platelet drugs like aspirin and clopidogrel, and the tight control of serum glucose. Cilostazol is currently the only drug available that actually improves functional status and maximal walking distance although the exact mechanism of this drug is not known. 1 7 Growth of collateral arteries upon arterial obstruction is a naturally occurring phenomenon in patients with both peripheral as well as CAD and the importance of collateral ow under ischaemic conditions has been recognized in both experimental and clinical studies. 1 8 After birth, blood vessels can grow either via the process of angiogenesis or via the process of arteriogenesis. Angiogenesis is the formation of capillary networks via the sprouting of endothelial cells and is mediated via hypoxia and the release of hypoxia inducible factor-1 (HIF-1). The term arteriogenesis was introduced by Schaper and is now generally accepted as a process distinct from angiogenesis. 7 Arteriogenesis is the proliferation of pre-existing vascular connections into functional collateral conduit arteries. According to the law of Hagen-Poiseuille, maximal ow depends on vessel radius to the fourth power, which means that small changes in vessel diameter result in large changes in blood ow. This process is far more ef cient in restoring bulk blood ow than the development of numerous smalldiameter capillaries as observed during angiogenesis. 1 9 The main stimulus for arteriogenesis is an increase in shear stress due to the development of a pressure gradient across the collateral pathways upon arterial occlusion. This increase in shear stress leads to an upregulation of adhesion molecules (ICAM, VCAM, selectins) on the endothelium. Circulating monocytes are attracted and migrate into the vessel wall, giving rise to the production of various cytokines and growth factors. 8 In a large group of patients with PAD, the formation of collateral arteries is insuf cient to restore blood ow and to meet the oxygen demand of regions distal of a vessel occlusion under working conditions, giving rise to intermittent claudication. Therefore, positive modulation of collateral artery growth constitutes a promising concept for treatment of arterial occlusive diseases. However, although the rst uncontrolled studies reported positive results, conrmation in randomized trials is still awaited. The TRAFFIC-trial showed bene cial effects for b-FGF treatment, but only in a secondary intention-to-treat analysis. 1 6 Other randomized trials such as the VIVA-trial using VEGF 2 0 or the AGENT-trial and FIRST-trial using b-FGF were also negative with regard to their primary outcomes. 2 1 ,2 2 We have shown that intra-arterial infusion of GM-CSF for a period of 1 week caused a marked enhancement of collateral growth in a rabbit hind limb model. 1 3 In contrast with other arteriogenic substances, GM-CSF induces arteriogenesis even when administered subcutaneously or intravenously since it acts upon circulating monocytes, increasing their lifespan via inhibition of apoptosis. 2 3 GM-CSF is already clinically available to treat chemotherapy-induced neutropenia and, moreover, it inhibits atherogenesis, 2 4 ,2 5 which is a serious possible side effect of other angiogenic and arteriogenic substances like MCP-1 and VEGF. 2 6 ,2 7 Seiler showed that GM-CSF increases collateral ow index (ratio of distal and proximal pressure during maximal balloon in ation) in patients with CAD 1 4 and this was actually the rst randomized study showing pharmacological modulation of collateral artery growth as assessed with a validated and objective intracoronary-derived haemodynamic measurement. 2 8 ,2 9 Based upon pharmacokinetical and toxicological studies, a dose of 10 mg/kg has been selected for current clinical applications and therefore we have chosen the same dosage for this clinical study. Subcutaneous application was selected since it was shown to have an improved toxicity and ef cacy pro le compared with intravenous administration. 3 0 This trial serves to determine whether subcutaneous treatment with GM-CSF has a bene cial effect on the maximal walking distance of patients with intermittent claudication. The study is designed as a 'proof-of-principle' study and therefore the walking distance at day 14 serves as the primary endpoint. In addition, new parameters have been introduced that may serve as additive measurements to detect the in uence of substances on collateral ow in the peripheral circulation. 
